CeriBell

Ceribell raises its revenue forecast for fiscal 2026 to 28–31% and benefits from demand for its portable EEG system and the AI-based Clarity AI for real-time detection of nonconvulsive status epilepticus. Canaccord raises its price target from $25 to $26 and rates the stock as Buy. Analysts see potential for a rise to the all-time high, supported by product innovation and expected revenue growth. » Więcej na finanzen.net

Ceribell reported Q2 revenue of $28.1 million (up 33% year‑over‑year) with a record gross margin of 92%, but recorded a larger net loss of $0.51 per share (expectation: -$0.36). The company is advancing new products for delirium monitoring and pediatrics, received FDA clearances and plans to launch the delirium product in Q4. Ceribell raised its full‑year revenue outlook to $114–117 million, refinanced its credit facility and, despite rising operating expenses, remains on a growth path; the stock rose after the results. Management emphasized a long‑term vision to establish EEG as a vital sign, while high spending and legal disputes were cited as risks. » Więcej na de.investing.com

The U.S. Centers for Medicare & Medicaid Services approved a New Technology Add-on Payment (NTAP) for CeriBell’s Delirium Monitor System, enabling an additional payment of up to $2,171 per qualifying Medicare case starting October 1, 2026. The decision follows the system’s FDA 510(k) clearance in December 2025; the device continuously analyzes EEG segments to detect and monitor delirium and complements CeriBell’s existing seizure detection. After the announcement, CeriBell’s share price rose by around 3%. » Więcej na de.investing.com